Table 2

Results of stress MPI in 522 participants randomized to screening, grouped according to various risk stratification schemes

Total normal MPITotal abnormal MPINon-MPI abnormalitiesSmall defectModerate/large defect
Framingham score
    Low risk (n = 135)104 (77.0)31 (23.0)9 (6.7)14 (10.4)8 (5.9)
    Intermediate/high risk (n = 387)305 (78.8)82 (21.2), P = 0.7221 (5.4)36 (9.3)25 (6.5)
UKPDS risk engine
    Low risk (n = 241)195 (80.9)46 (19.1)14 (5.8)20 (8.3)12 (5.0)
    Intermediate/high risk (n = 276)210 (76.1)66 (23.9), P = 0.216 (5.8)30 (10.9)20 (7.3)
ALFEDIAM/SFC criteria
    Low risk (n = 196)159 (81.1)37 (18.9)6 (3.1)17 (8.7)14 (7.1)
    High risk (n = 326)250 (76.7)76 (23.3), P = 0.2724 (7.4)33 (10.1)19 (5.8)
Metabolic syndrome
    No (n = 157)120 (76.4)37 (23.6)11 (7.0)18 (11.5)8 (5.1)
    Yes (n = 365)289 (79.2)76 (20.8), P = 0.4919 (5.2)32 (8.8)25 (6.9)
  • Data are n (%). A total of 19 participants not categorized due to missing data. P values reflect comparison of total abnormal MPI in two risk groups (see text). Non-MPI abnormalities = ischemic electrocardiogram changes during adenosine infusion, transient ischemic dilation, or baseline left ventricular dysfunction.